Levemir Flextouch (Insulin Detemir)

Insulin detemir is an insulin analogue in which a fatty‑acid side chain promotes reversible binding to albumin after subcutaneous injection. This creates a subcutaneous depot that releases insulin slowly, allowing prolonged activation of insulin receptors on muscle, adipose and liver cells, thereby enhancing glucose uptake and suppressing hepatic glucose production over a 24‑hour period.

The dose of Levemir Flextouch is individualized. A qualified healthcare professional determines the starting amount and subsequent adjustments based on the patient’s blood‑glucose readings, carbohydrate intake, physical activity, renal and hepatic function, and overall treatment goals. Patients should follow the prescriber’s instructions and regularly monitor glucose to guide dose changes.

Safety data for insulin detemir in pregnancy are limited, and the product is classified as pregnancy category unknown. It may be used when the benefits outweigh potential risks, under close medical supervision. Insulin is generally considered compatible with breastfeeding, but mothers should discuss any concerns with their healthcare provider.

To request Levemir Flextouch, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping options and necessary import documentation.

Levemir Flextouch (insulin detemir) is a long‑acting analogue that provides a relatively flat 24‑hour glucose‑lowering profile with a lower risk of pronounced peaks compared with intermediate‑acting NPH insulin. Compared with other long‑acting analogues such as insulin glargine, detemir has a shorter duration of action, which may require twice‑daily dosing in some patients.

Levemir Flextouch must be kept refrigerated between 2 °C and 8 °C (36 °F–46 °F). Protect the vial from light and avoid freezing. Do not shake the solution; gently roll if necessary to mix. Once removed from refrigeration, the product may be used for up to 28 days at room temperature, provided it remains clear and free of particles.

Levemir Flextouch is administered by subcutaneous injection using a compatible pen or syringe. Injection sites include the abdomen, thigh, or upper arm, rotating sites to reduce lipodystrophy. The dose is typically given once daily, though some patients may require twice‑daily dosing based on glycemic response. Patients should follow proper aseptic technique and needle‑disposal guidelines.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Rarely, patients may develop insulin antibodies that alter insulin action. Prompt recognition of symptoms and immediate medical attention are essential to mitigate these potentially life‑threatening events.

Levemir Flextouch should be avoided in individuals with known hypersensitivity to insulin detemir or any of the product’s excipients. It is also contraindicated in patients experiencing severe hypoglycemia until the condition is resolved, and in those for whom a rapid‑acting insulin is required for prandial control. Clinical judgment is required for each case.